Current Oncology (Feb 2023)

Direct Comparison of Two Different Definitions with Biochemical Recurrence after Low-Dose-Rate Brachytherapy for Prostate Cancer

  • Shinichi Takeuchi,
  • Koji Iinuma,
  • Keita Nakane,
  • Masahiro Nakano,
  • Makoto Kawase,
  • Kota Kawase,
  • Manabu Takai,
  • Daiki Kato,
  • Takayuki Mori,
  • Hirota Takano,
  • Tomoyasu Kumano,
  • Masayuki Matsuo,
  • Takuya Koie

DOI
https://doi.org/10.3390/curroncol30030212
Journal volume & issue
Vol. 30, no. 3
pp. 2792 – 2800

Abstract

Read online

We aimed to determine whether biochemical recurrence-free survival (BRFS) of patients with prostate cancer (PCa) who received low-dose-rate brachytherapy (LDR-BT) differed according to the definition of biochemical recurrence (BCR) after radical prostatectomy (RP) and the definition given by the Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS). We reviewed the clinical records of 476 consecutive patients with PCa who received LDR-BT at the Gifu University Hospital. The primary endpoint of this study was the difference in BRFS between the two aforementioned definitions. When the follow-up period ended, 74 (15.5%) and 20 (4.2%) patients had BCR according to the RP and J-POPS definitions, respectively. The 5-year BRFS rates were 85.0% and 96.9% for the RP and J-POPS definitions, respectively (p p = 0.050). According to the J-POPS definition, the 5-year BRFS rates were 94.1% and 97.8% in the groups aged p = 0.005). The definition of recurrence in LDR-BT may need to be reconsidered.

Keywords